{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:09:21Z","timestamp":1789913361363,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,12]]},"DOI":"10.7759\/cureus.77320","type":"journal-article","created":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T15:10:16Z","timestamp":1736694616000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of Filgrastim on Mortality During Induction Chemotherapy in Childhood B-Cell Non-Hodgkin Lymphoma"],"prefix":"10.7759","author":[{"given":"Madiha","family":"Jameel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Wali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Muhammad Jawad","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najma","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfana Ishaq","family":"Sindhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2141960","article-title":"Non-Hodgkin lymphoma treatment in middle-income countries in Latin America: perspective of the Latin American Study Group of Lymphoproliferative Disorders [Grupo de Estudio de Linfoproliferativos de Latino Am\u00e9rica (GELL)]","volume":"27","author":"Villela L","year":"2022","unstructured":"Villela L, Torre-Viera M, Idrobo-Quintero H, Beltran BE. Non-Hodgkin lymphoma treatment in middle-income countries in Latin America: perspective of the Latin American Study Group of Lymphoproliferative Disorders [Grupo de Estudio de Linfoproliferativos de Latino Am\u00e9rica (GELL)]. Hematology. 2022, 27:1208-16. 10.1080\/16078454.2022.2141960","journal-title":"Hematology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2019.043","article-title":"Malnutrition, sepsis, and tumor lysis syndrome are associated with an increased rate of acute mortality in mature B cell non-Hodgkin lymphoma in a pediatric population-study from tertiary care hospital in Pakistan","volume":"11","author":"Mansoor R","year":"2019","unstructured":"Mansoor R, Saeed H, Wali RM, Rehman P, Abubakar M. Malnutrition, sepsis, and tumor lysis syndrome are associated with an increased rate of acute mortality in mature B cell non-Hodgkin lymphoma in a pediatric population-study from tertiary care hospital in Pakistan. Mediterr J Hematol Infect Dis. 2019, 11:e2019043. 10.4084\/MJHID.2019.043","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-023-03238-9","article-title":"Clinical characteristics and\u00a0prognostic factors for primary pediatric and adolescent non-Hodgkin lymphomas of the gastrointestinal tract: a population-based study","volume":"21","author":"Wu P","year":"2023","unstructured":"Wu P, Zhu D, Lou Y, Wang X. Clinical characteristics and\u00a0prognostic factors for primary pediatric and adolescent non-Hodgkin lymphomas of the gastrointestinal tract: a population-based study. World J Surg Oncol. 2023, 21:353. 10.1186\/s12957-023-03238-9","journal-title":"World J Surg Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant M","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, et al.. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010, 116:3724-34. 10.1182\/blood-2010-05-282632","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/0971-4065.57102","article-title":"Tumor lysis and acute renal failure in Burkitt's lymphoma: a review on pathophysiology and management","volume":"19","author":"Senbanjo IO","year":"2009","unstructured":"Senbanjo IO. Tumor lysis and acute renal failure in Burkitt's lymphoma: a review on pathophysiology and management. Indian J Nephrol. 2009, 19:83-6. 10.4103\/0971-4065.57102","journal-title":"Indian J Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2020.1865493","article-title":"Clinical profile, outcome and challenges in the management of pediatric Burkitt lymphoma: a single center experience","volume":"38","author":"Chauhan P","year":"2021","unstructured":"Chauhan P, Gupta A, Mandelia A, Yadav S, Rahman K, Nityanand S. Clinical profile, outcome and challenges in the management of pediatric Burkitt lymphoma: a single center experience. Pediatr Hematol Oncol. 2021, 38:305-18. 10.1080\/08880018.2020.1865493","journal-title":"Pediatr Hematol Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199448050-00007","article-title":"Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia","volume":"48","author":"Frampton JE","year":"1994","unstructured":"Frampton JE, Lee CR, Faulds D. Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs. 1994, 48:731-60. 10.2165\/00003495-199448050-00007","journal-title":"Drugs"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.22541\/au.171732078.85936972\/v1","article-title":"Granulocyte colony stimulating factor as primary prophylaxis to reduce acute mortality during Induction chemotherapy in childhood B cell non-Hodgkin lymphoma: report from tertiary cancer care hospital","author":"Jameel M","year":"2024","unstructured":"Jameel M, Wali RM, Zaidi SMJ, Ishaq I, Shaheen N. Granulocyte colony stimulating factor as primary prophylaxis to reduce acute mortality during Induction chemotherapy in childhood B cell non-Hodgkin lymphoma: report from tertiary cancer care hospital. Authorea. 2024, 10.22541\/au.171732078.85936972\/v1","journal-title":"Authorea"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7203","article-title":"Revised International Pediatric Non-Hodgkin Lymphoma Staging System","volume":"33","author":"Rosolen A","year":"2015","unstructured":"Rosolen A, Perkins SL, Pinkerton CR, et al.. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol. 2015, 33:2112-8. 10.1200\/JCO.2014.59.7203","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00404-3","article-title":"Burkitt lymphoma","volume":"8","author":"L\u00f3pez C","year":"2022","unstructured":"L\u00f3pez C, Burkhardt B, Chan JK, et al.. Burkitt lymphoma. Nat Rev Dis Primers. 2022, 8:78. 10.1038\/s41572-022-00404-3","journal-title":"Nat Rev Dis Primers"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001709","article-title":"Clinicopathologic characterization of children with b-cell non-Hodgkin lymphoma over 10 years at a tertiary center in Cape Town, South Africa","volume":"42","author":"Kriel M","year":"2020","unstructured":"Kriel M, Davidson A, Pillay K, Hendricks M, Phillips LA. Clinicopathologic characterization of children with b-cell non-Hodgkin lymphoma over 10 years at a tertiary center in Cape Town, South Africa. J Pediatr Hematol Oncol. 2020, 42:e219-27. 10.1097\/MPH.0000000000001709","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte C","year":"2007","unstructured":"Patte C, Auperin A, Gerrard M, et al.. Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007, 109:2773-80. 10.1182\/blood-2006-07-036673","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40365","article-title":"Infection-associated mortality during induction chemotherapy in group b intermediate-risk pediatric Burkitt's lymphoma","volume":"15","author":"Ibne Ali Jaffari SM","year":"2023","unstructured":"Ibne Ali Jaffari SM, Hashmi M, Hashmi AW, et al.. Infection-associated mortality during induction chemotherapy in group b intermediate-risk pediatric Burkitt's lymphoma. Cureus. 2023, 15:e40365. 10.7759\/cureus.40365","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5581\/1516-8484.20120093","article-title":"Clinical course and prognostic factors of children with Burkitt's lymphoma in a developing country: the experience of a single centre in Brazil","volume":"34","author":"Cunha KC","year":"2012","unstructured":"Cunha KC, Oliveira MC, Gomes AC, de Castro LP, Viana MB. Clinical course and prognostic factors of children with Burkitt's lymphoma in a developing country: the experience of a single centre in Brazil. Rev Bras Hematol Hemoter. 2012, 34:361-6. 10.5581\/1516-8484.20120093","journal-title":"Rev Bras Hematol Hemoter"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22905","article-title":"Treatment of children with B-cell non-Hodgkin lymphoma in a low-income country","volume":"56","author":"Moleti ML","year":"2011","unstructured":"Moleti ML, Al-Hadad SA, Al-Jadiry MF, et al.. Treatment of children with B-cell non-Hodgkin lymphoma in a low-income country. Pediatr Blood Cancer. 2011, 56:560-7. 10.1002\/pbc.22905","journal-title":"Pediatr Blood Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0762","article-title":"The evolution of value with filgrastim in oncology","volume":"15","author":"Cornes P","year":"2019","unstructured":"Cornes P, Krendyukov A. The evolution of value with filgrastim in oncology. Future Oncol. 2019, 15:1525-33. 10.2217\/fon-2018-0762","journal-title":"Future Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith TJ","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, et al.. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015, 33:3199-212. 10.1200\/JCO.2015.62.3488","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith TJ","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH, et al.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006, 24:3187-205. 10.1200\/JCO.2006.06.4451","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.106","article-title":"Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials","volume":"22","author":"Sung L","year":"2004","unstructured":"Sung L, Nathan PC, Lange B, Beyene J, Buchanan GR. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol. 2004, 22:3350-6. 10.1200\/JCO.2004.09.106","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.716","article-title":"Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom","volume":"16","author":"Foss\u00e5 SD","year":"1998","unstructured":"Foss\u00e5 SD, Kaye SB, Mead GM, et al.. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol. 1998, 16:716-24. 10.1200\/JCO.1998.16.2.716","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/309635-impact-of-filgrastim-on-mortality-during-induction-chemotherapy-in-childhood-b-cell-non-hodgkin-lymphoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T15:10:17Z","timestamp":1736694617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/309635-impact-of-filgrastim-on-mortality-during-induction-chemotherapy-in-childhood-b-cell-non-hodgkin-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,12]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.77320","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,12]]}}}